SCHEMBL4778352

SCHEMBL4778352

Cc1ccc(CN2CCN(C(c3ccc(Cl)cc3Cl)C(N)C=O)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
HPN P05981 1/20 0.38
CHRM2 P08172 1/20 0.38
ADRA2A P08913 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CHRM1 P11229 1/20 0.38
DRD2 P14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776397 0.90 CYP3A4 (0.52) ALDH1A1LMNAKDM4EMAPTMAPK1
SCHEMBL4775561 0.89 MAPT (0.43) MAPTSIGMAR1KCNH2ATMMEN1
SCHEMBL4778381 0.84 LSS (0.40) SIGMAR1CYP3A4MEN1KMT2A
SCHEMBL4773088 0.80 SIGMAR1 (0.36) ALDH1A1LMNAPOLBKDM4EMAPT
SCHEMBL4778576 0.80 FAAH (0.47) ALDH1A1LMNAKDM4EKCNH2
SCHEMBL4771297 0.78 NPSR1 (0.46) ALDH1A1LMNAPOLBNPSR1KDM4E
SCHEMBL4776514 0.77 SIGMAR1 (0.36) ALDH1A1POLBKDM4ESIGMAR1CYP3A4
SCHEMBL4773571 0.73 CNR1 (0.48) CNR1OPRM1OPRK1
SCHEMBL4774991 0.71 LMNA (0.39) ALDH1A1LMNANPSR1MAPTMAPK1
SCHEMBL15901736 0.69 ALDH1A1 (0.71) ALDH1A1LMNAPOLBKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed